INTENSITY THERAPEUTICS, INC. (INTS) Profit Breakdown
- 2026-06-30: Reportable -$3.01M.
- 2025-06-30: Reportable -$2.54M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2022-06-30 to 2026-06-30
- Data captured
Profit by product
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$3.01M |
| 2025-06-30 | -$2.54M |
Operating income: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$3.08M |
| 2025-06-30 | -$2.71M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |